{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:08:08Z","timestamp":1791313688690,"version":"4.3.1"},"reference-count":176,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.nucmedbio.2007.04.001","type":"journal-article","created":{"date-parts":[[2007,6,11]],"date-time":"2007-06-11T09:04:40Z","timestamp":1181552680000},"page":"757-778","source":"Crossref","is-referenced-by-count":212,"title":["Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view"],"prefix":"10.1016","volume":"34","author":[{"given":"C. Andrew","family":"Boswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2007.04.001_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrd1413","article-title":"Antibody-targeted radiation cancer therapy","volume":"3","author":"Milenic","year":"2004","journal-title":"Nat Rev Drug Disc"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/153303460500400406","article-title":"Cancer therapy with radiolabeled and drug\/toxin-conjugated antibodies","volume":"4","author":"Govindan","year":"2005","journal-title":"Tech Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.04.001_bib3","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.2349\/biij.2.3.e23","article-title":"Radioimmunotherapy: a brief overview","volume":"2","author":"Ng","year":"2006","journal-title":"Biomed Imaging Interv J"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.04.001_bib4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14737140.6.3.445","article-title":"Review of clinical radioimmunotherapy","volume":"6","author":"Pohlman","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib5","volume":"vol 3","author":"Ehrlich","year":"1960"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.04.001_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1749-6632.1955.tb45950.x","article-title":"Tissue localizing antibodies","volume":"59","author":"Pressman","year":"1955","journal-title":"Ann N Y Acad Sci"},{"issue":"450","key":"10.1016\/j.nucmedbio.2007.04.001_bib7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/248704a0","article-title":"In vivo localization of radiolabeled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice","volume":"248","author":"Mach","year":"1974","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.04.001_bib8","first-page":"1","article-title":"Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G","volume":"34","author":"Goldenberg","year":"1974","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.1993.11.4.698","article-title":"Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease","volume":"11","author":"Bierman","year":"1993","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.04.001_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/1744666X.1.1.47","article-title":"Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal","volume":"1","author":"Sharkey","year":"2005","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jama.293.7.855","article-title":"Molecular imaging in the clinical arena","volume":"293","author":"Jaffer","year":"2005","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.nucmedbio.2007.04.001_bib13","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1158\/1078-0432.CCR-05-1302","article-title":"The progress and promise of molecular imaging probes in oncologic drug development","volume":"11","author":"Kelloff","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00259-006-0116-4","article-title":"Which radionuclides will nuclear oncology need tomorrow?","volume":"33","author":"Barbet","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-8140(02)00374-2","article-title":"Tumour therapy with radionuclides: assessment of progress and problems","volume":"66","author":"Carlsson","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib16","first-page":"1685","article-title":"Copper-64-labeled antibodies for PET imaging","volume":"33","author":"Anderson","year":"1992","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.04.001_bib17","first-page":"850","article-title":"Preparation, biodistribution and dosimetry of 64Cu-labeled anti-colorectal carcinoma monoclonal antibody (MAb) fragments 1A3 F(ab\u2032)2","volume":"36","author":"Anderson","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib18","first-page":"28P","article-title":"Optimization of the preparation of 64Cu-labeled monoclonal antibody (MAb) fragments [1A3-F(ab\u2032)2] for improved biodistribution","volume":"34","author":"Anderson","year":"1993","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.04.001_bib19","first-page":"1663","article-title":"Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice","volume":"44","author":"Verel","year":"2004","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.04.001_bib20","first-page":"1271","article-title":"89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies","volume":"44","author":"Verel","year":"2004","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/108497803322287745","article-title":"Long-lived positron emitters 89Zr and 124I for scouting of therapeutic radioimmunoconjugates with PET","volume":"18","author":"Verel","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib22","first-page":"164S","article-title":"The promise of immunoPET in radioimmunotherapy","volume":"46","author":"Verel","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib23","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-05-2137","article-title":"Performance of immunoPET with 89Zr-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients","volume":"12","author":"Borjesson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib24","series-title":"Radioactive decay tables","author":"Kocher","year":"1981"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1103\/RevModPhys.24.28","article-title":"Range\u2013energy relations for electrons and the determination of beta-ray end-point energies by absorption","volume":"24","author":"Katz","year":"1952","journal-title":"Rev Mod Phys"},{"issue":"2 Pt 2","key":"10.1016\/j.nucmedbio.2007.04.001_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1118\/1.597048","article-title":"Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles","volume":"20","author":"Leichner","year":"1993","journal-title":"Med Phys"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.04.001_bib27","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib28","first-page":"134P","article-title":"Comparison of 67Cu and 64Cu as potential radionuclides for radiotherapy","volume":"34","author":"Anderson","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/09553008914550421","article-title":"Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu","volume":"55","author":"Apelgot","year":"1989","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib30","first-page":"2635","article-title":"High-linear energy transfer (LET) \u03b1 versus low-LET \u03b2 emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab\u2032 fragments in a human colonic cancer model","volume":"59","author":"Behr","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib31","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1088\/0031-9155\/49\/16\/016","article-title":"Targeted alpha therapy for cancer","volume":"49","author":"Allen","year":"2004","journal-title":"Phys Med Biol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.04.001_bib32","first-page":"114","article-title":"Research on 212Pb- and 212Bi-radiopharmaceuticals for therapy","volume":"10","author":"Fang","year":"1997","journal-title":"J Isot"},{"issue":"91","key":"10.1016\/j.nucmedbio.2007.04.001_bib33","first-page":"109","article-title":"Potential in vivo generator for alpha-particle therapy with 212Bi: presentation of a system to minimize escape of daughter nuclide after decay of 212Pb to 212Bi","volume":"2003","author":"Henriksen","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0090-8258(89)80040-X","article-title":"The effect of the \u03b1-emitting radionuclide 212Pb on human ovarian carcinoma: a potential new form of therapy","volume":"32","author":"Rotmensch","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0360-3016(95)02119-1","article-title":"The use of 212Pb-labeled monoclonal antibody in the treatment of murine erthyroleukemia","volume":"34","author":"Ruble","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.nucmedbio.2005.06.009","article-title":"Pre-targeted radioimmunotherapy in tumored mice using an in vivo 212Pb\/212Bi generator","volume":"32","author":"Su","year":"2005","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.04.001_bib37","first-page":"5806","article-title":"Production of carrier free 225Ac\/213Bi from 229Th for alpha-immunotherapy","volume":"44","author":"Apostolidis","year":"2001","journal-title":"J Labelled Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib38","first-page":"29","article-title":"Cancer treatment using 213Bi and 225Ac in radioimmunotherapy","author":"Apostolidis","year":"2001","journal-title":"Nucl News"},{"issue":"19","key":"10.1016\/j.nucmedbio.2007.04.001_bib39","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1021\/ac0580114","article-title":"Production of 225Ac from 229Th for targeted \u03b1 therapy","volume":"77","author":"Apostolidis","year":"2005","journal-title":"Anal Chem"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib40","first-page":"2008","article-title":"Response of LNCaP spheroids after treatment with an \u03b1-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)","volume":"61","author":"Ballangrud","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib41","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1158\/1078-0432.CCR-03-0800","article-title":"Alpha-particle emitting atomic generator 225Ac-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2\/neu expression","volume":"10","author":"Ballangrud","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.apradiso.2004.12.003","article-title":"Production of 225Ac for alpha particle mediated radioimmunotherapy","volume":"62","author":"Boll","year":"2005","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1040-8428(01)00113-5","article-title":"In vitro and pre-clinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers","volume":"39","author":"Allen","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib44","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/sj.bjc.6600838","article-title":"Pre-clinical studies of targeted a therapy for breast cancer using 213Bi-labeled-plasminogen activator inhibitor type 2","volume":"88","author":"Allen","year":"2003","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.04.001_bib45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1054\/bjoc.2000.1453","article-title":"Demonstration of highly specific toxicity of the \u03b1-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin's lymphoma cells","volume":"83","author":"Aurlien","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib46","first-page":"459","article-title":"Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labeled monoclonal antibody MOv18","volume":"20","author":"Andersson","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib47","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s00259-003-1308-9","article-title":"Combined effect of gefitinib (\u2018Iressa,\u2019 ZD1839) and targeted radiotherapy with 211At-EGF","volume":"30","author":"Sundberg","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib48","first-page":"40","article-title":"Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of 149Tb","volume":"17","author":"Allen","year":"1996","journal-title":"Nucl Med Biol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.04.001_bib49","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/09553000110094788","article-title":"Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an \u03b1-emitting radioimmunoconjugate and external \u03b3-irradiation","volume":"78","author":"Aurlien","year":"2002","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib50","first-page":"3031","article-title":"Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with \u03b1-Auger\/conversion electron- or \u03b1-emitters","volume":"5","author":"Behr","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.nucmedbio.2007.04.001_bib51","first-page":"1946","article-title":"Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you","volume":"46","author":"Boswell","year":"2005","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2007.04.001_bib52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s002590000272","article-title":"Therapeutic advantages of Auger electron- over \u03b2-emitting radiometals or radioiodine when conjugates to internalizing antibodies","volume":"27","author":"Behr","year":"2000","journal-title":"Eur J Nucl Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.04.001_bib53","first-page":"13N","article-title":"Radionuclides and radiopharmaceuticals for 2005","volume":"46","author":"Silberstein","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0031-6865(96)00051-9","article-title":"Quality assurance after process changes of the production of a therapeutic antibody","volume":"71","author":"Brass","year":"1996","journal-title":"Pharm Acta Helv"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.04.001_bib55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","article-title":"Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma","volume":"5","author":"Gordon","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib56","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d74 schedule","volume":"15","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib57","author":"Ellis"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib58","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1039\/b606410h","article-title":"Labelling monoclonal antibodies with macrocyclic radiometal complexes. A challenge for coordination chemists","author":"Kaden","year":"2006","journal-title":"Dalton Trans"},{"issue":"14","key":"10.1016\/j.nucmedbio.2007.04.001_bib59","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1021\/jm060317v","article-title":"Small animal PET\/CT imaging using 86Y-CHX-A\u2033-octreotide: validation of a novel CHX-A\u2033 derivative suitable for peptide conjugation","volume":"49","author":"Clifford","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib60","doi-asserted-by":"crossref","first-page":"7080s","DOI":"10.1158\/1078-0432.CCR-1004-0019","article-title":"Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A\u2033-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.04.001_bib61","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00259-003-1228-8","article-title":"In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage","volume":"30","author":"Vandenbulcke","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib62","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/jm030383m","article-title":"Comparative in vivo stability of 64Cu-labeled cross-bridged and conventional tetraazamacrocyclic complexes","volume":"47","author":"Boswell","year":"2004","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib63","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1038\/nprot.2006.431","article-title":"Radiolabeling of TETA- and CB-TE2A-conjugated peptides with 64Cu","volume":"1","author":"Wadas","year":"2007","journal-title":"Nat Prot"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib64","author":"The Dow Chemical Co."},{"issue":"9","key":"10.1016\/j.nucmedbio.2007.04.001_bib65","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nbt0905-1065","article-title":"Upping the ante on antibodies","volume":"23","author":"Baker","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"1\u20132","key":"10.1016\/j.nucmedbio.2007.04.001_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-1759(00)00342-2","article-title":"Design and application of diabodies, triabodies and tetrabodies for cancer targeting","volume":"248","author":"Todorovska","year":"2001","journal-title":"J Immunol Methods"},{"issue":"15","key":"10.1016\/j.nucmedbio.2007.04.001_bib67","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1073\/pnas.150228297","article-title":"High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a 64Cu-labeled engineered antibody fragment","volume":"97","author":"Wu","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib68","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/1078-0432.CCR-03-0576","article-title":"Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer","volume":"10","author":"Wong","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib69","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-04-2008","article-title":"Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenograft with an 124I labeled anti-HER2 diabody","volume":"65","author":"Robinson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib70","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1158\/0008-5472.622.65.2","article-title":"Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single chain Fv-Fc antibody fragments","volume":"65","author":"Kenanova","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.04.001_bib71","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/cbr.1999.14.153","article-title":"Pre-targeting with the affinity enhancement system for radioimmunotherapy","volume":"14","author":"Barbet","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib72","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","article-title":"Antibody pre-targeting advances cancer radioimmunodetection and radioimmunotherapy","volume":"24","author":"Goldenberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/0929867053363225","article-title":"Recent advances in pre-targeted radioimmunotherapy","volume":"12","author":"Gruaz-Guyon","year":"2005","journal-title":"Curr Med Chem"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.04.001_bib74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/cbr.1999.14.381","article-title":"Radiation absorbed dose estimation for 90Y-DOTA-biotin with pre-targeted NR-LU-10\/streptavidin","volume":"14","author":"Breitz","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib75","first-page":"131","article-title":"Clinical optimization of pre-targeted radioimmunotherapy with antibody\u2013streptavidin conjugate and 90Y-DOTA-biotin","volume":"41","author":"Breitz","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib76","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1073\/pnas.97.4.1802","article-title":"Cure of human carcinoma xenografts by a single dose of pre-targeted 90Y with negligible toxicity","volume":"97","author":"Axworthy","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.nucmedbio.2007.04.001_bib77","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V98.8.2535","article-title":"A comparative evaluation of conventional and pre-targeted radioimmunotherapy of CD20-expressing lymphomas xenografts","volume":"98","author":"Press","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.04.001_bib78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1040-8428(01)00133-0","article-title":"Pre-targeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL)","volume":"40","author":"Weiden","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib79","first-page":"406","article-title":"Phase II trial of 90Y-DOTA-biotin pre-targeted by NR-LU-10 antibody\/streptavidin in patients with metastatic colon cancer","volume":"6","author":"Knox","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib80","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/nm1322","article-title":"Signal amplification in molecular imaging by pre-targeting a multivalent, bispecific antibody","volume":"11","author":"Sharkey","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib81","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/sj.gt.3302671","article-title":"A membrane antibody receptor for noninvasive imaging of gene expression","volume":"13","author":"Roffler","year":"2006","journal-title":"Gene Ther"},{"issue":"17","key":"10.1016\/j.nucmedbio.2007.04.001_bib82","first-page":"3825","article-title":"Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives","volume":"55","author":"Behr","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib83","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.nucmedbio.2007.04.001_bib84","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1158\/0008-5472.CAN-05-0662","article-title":"Penetratin improves tumor retention of single-chain antibodies: a novel step towards optimization of radioimmunotherapy of solid tumors","volume":"65","author":"Jain","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib85","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1126\/science.1130482","article-title":"Considering therapeutic antibodies","volume":"313","author":"Vitetta","year":"2006","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.04.001_bib86","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMp068087","article-title":"T-cell costimulation \u2014 biology, therapeutic potential, and challenges","volume":"355","author":"Sharpe","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.04.001_bib87","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.04.001_bib88","first-page":"36N","article-title":"NeutroSpec withdrawn from market","volume":"47","author":"Newsbriefs","year":"2006","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib89","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/cbr.2006.21.285","article-title":"Recombinant antibodies: from the laboratory to the clinic","volume":"21","author":"Albrecht","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"issue":"9","key":"10.1016\/j.nucmedbio.2007.04.001_bib90","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nbt0905-1073","article-title":"Monoclonal antibody successes in the clinic","volume":"23","author":"Reichert","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib91","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nbt0901-819","article-title":"Monoclonal antibodies in the clinic","volume":"19","author":"Reichert","year":"2001","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.04.001_bib92","first-page":"110","article-title":"Therapeutic monoclonal antibodies: trends in development and approval in the US","volume":"4","author":"Reichert","year":"2002","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib93","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/3460","article-title":"Antibodies come back from the brink","volume":"16","author":"Holliger","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib94","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.nucmedbio.2007.04.001_bib95","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nbt0706-769","article-title":"Biopharmaceutical benchmarks 2006","volume":"24","author":"Walsh","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.04.001_bib96","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14712598.6.8.787","article-title":"Development of antibodies for cancer therapy","volume":"6","author":"Wilkins","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib97","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib98","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev.med.54.101601.152442","article-title":"Monoclonal antibody therapy for cancer","volume":"54","author":"von Mehren","year":"2003","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib99","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1309\/5CWPU41AFR1VYM3F","article-title":"Targeted therapies for cancer 2004","volume":"122","author":"Ross","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev.med.52.1.125","article-title":"Antibody-targeted immunotherapy for treatment of malignancy","volume":"52","author":"White","year":"2001","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.04.001_bib101","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF03027399","article-title":"Current status of cancer therapy with radiolabeled monoclonal antibody","volume":"19","author":"Oriuchi","year":"2005","journal-title":"Ann Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib102","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1309\/Y6LPC0LR726L9DX9","article-title":"Anticancer antibodies","volume":"9","author":"Ross","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib103","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrd1386","article-title":"Monoclonal antibodies market","volume":"3","author":"Reichert","year":"2004","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib104","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nbt1204-1513","article-title":"Recombinant protein therapeutics \u2014 success rates, market trends, and values to 2010","volume":"22","author":"Pavlou","year":"2004","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.04.001_bib105","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1349-7006.2004.tb02180.x","article-title":"What are the reasons for negative phase III trials of molecular-target-based drugs?","volume":"95","author":"Saijo","year":"2004","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.nucmedbio.2007.04.001_bib106","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","article-title":"Arming antibodies: prospects and challenges for immunoconjugates","volume":"23","author":"Wu","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib107","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3322\/canjclin.56.4.226","article-title":"Targeted therapy of cancer: new prospects for antibodies and immunoconjugates","volume":"56","author":"Sharkey","year":"2006","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.04.001_bib108","first-page":"182","article-title":"Technology evaluation: nimotuzumab, the Center of Molecular Immunology\/YM BioSciences\/Oncoscience","volume":"7","author":"Spicer","year":"2005","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib109","article-title":"Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188Re","volume":"22","author":"Casaco","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.nucmedbio.2007.04.001_bib110","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/00006231-200212000-00002","article-title":"99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor","volume":"23","author":"Vallis","year":"2002","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.04.001_bib111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cbr.2006.21.81","article-title":"What ails solid tumor radioimmunotherapy?","volume":"21","author":"Divgi","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib112","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/ijc.2910610421","article-title":"Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability","volume":"61","author":"Blumenthal","year":"1995","journal-title":"Int J Cancer"},{"issue":"S1","key":"10.1016\/j.nucmedbio.2007.04.001_bib113","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3816\/CLM.2004.s.002","article-title":"Radiometals as payloads for radioimmunotherapy for lymphoma","volume":"5","author":"DeNardo","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib114","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1634\/theoncologist.9-2-160","article-title":"Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma","volume":"9","author":"Vose","year":"2004","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.nucmedbio.2007.04.001_bib115","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab","volume":"11","author":"Linden","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib116","author":"Immunomedics, Inc."},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib117","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/108497802320970307","article-title":"Radioimmunoscintigraphy (RIS) with bectumomab (99mTc-labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL)","volume":"17","author":"Lamonica","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"issue":"23 Suppl S","key":"10.1016\/j.nucmedbio.2007.04.001_bib118","first-page":"S5764","article-title":"Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment","volume":"55","author":"Blend","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib119","first-page":"533","article-title":"67Cu- versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma","volume":"5","author":"DeNardo","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib120","author":"Peregrine Pharmaceuticals, Inc."},{"issue":"11","key":"10.1016\/j.nucmedbio.2007.04.001_bib121","doi-asserted-by":"crossref","first-page":"214A","DOI":"10.1182\/blood.V104.11.750.750","article-title":"Tumor targeting, dosimetry and clinical response data for LymphoRad-131 in patients with relapsed\/refractory non-Hodgkin's lymphoma","volume":"104","author":"Belch","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib122","first-page":"922s","article-title":"Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging","volume":"50","author":"Beatty","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib123","first-page":"1646","article-title":"Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study","volume":"30","author":"Bischof-Delaloye","year":"1989","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib124","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ijc.2910440218","article-title":"Comparison of therapeutic efficacy and host toxicity of two different 131I-labeled antibodies and their fragments in the GW-39 colonic cancer xenograft model","volume":"44","author":"Blumenthal","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib125","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/1078-0432.CCR-04-2329","article-title":"A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake","volume":"11","author":"Scott","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib126","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1158\/1078-0432.CCR-04-2330","article-title":"Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma","volume":"11","author":"Chong","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"23 Suppl S","key":"10.1016\/j.nucmedbio.2007.04.001_bib127","first-page":"S5881","article-title":"Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49","volume":"55","author":"Buchsbaum","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib128","first-page":"3095","article-title":"High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial","volume":"6","author":"Tempero","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib129","series-title":"Cancer therapy with radiolabeled antibodies","first-page":"63","article-title":"Advanced methods for radiolabeling monoclonal antibodies with therapeutic radionuclides","author":"Gansow","year":"1995"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib130","author":"Immunomedics, Inc"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib131","author":"Immunomedics, Inc"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib132","author":"Immunomedics, Inc"},{"issue":"27","key":"10.1016\/j.nucmedbio.2007.04.001_bib133","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","article-title":"Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results","volume":"23","author":"Liersch","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib134","author":"Immunomedics, Inc"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib135","first-page":"5842","article-title":"A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer","volume":"9","author":"Wong","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.04.001_bib136","first-page":"1180","article-title":"Radioimmunotherapy for breast cancer using 111In\/90Y-BrE-3: results of a phase I clinical trial","volume":"38","author":"DeNardo","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib137","first-page":"1735","article-title":"Yttrium-90\/Indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer","volume":"17","author":"DeNardo","year":"1997","journal-title":"Anticancer Res"},{"issue":"14S","key":"10.1016\/j.nucmedbio.2007.04.001_bib138","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/jco.2004.22.14_suppl.2554","article-title":"Combined modality radioimmunotherapy (RIT) in metastatic prostate and breast cancer using paclitaxel and a MUC-1 monoclonal antibody, m170, linked to 90Y: a phase I trial","volume":"22","author":"Richman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib139","first-page":"5921s","article-title":"High-dose 90Y-Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial","volume":"55","author":"Schrier","year":"1995","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.04.001_bib140","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.bjc.6600248","article-title":"Serum CEA and CA 15-3 as prognostic factors in primary breast cancer","volume":"86","author":"Ebeling","year":"2002","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib141","first-page":"858","article-title":"Phase I\/II clinical radioimmunotherapy with an 131I-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG","volume":"38","author":"Behr","year":"1997","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.04.001_bib142","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00006231-200303000-00009","article-title":"Contribution of 99mTc-anti-carcinoembryonic antigen antibody and 99mTc-sestamibi scintimammography in the evaluation of high risk palpable breast lesions","volume":"24","author":"Sanidas","year":"2003","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib143","first-page":"842","article-title":"Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts","volume":"39","author":"DeNardo","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib144","first-page":"4263","article-title":"Cilengitide targeting of alpha-v-beta-3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts","volume":"62","author":"Burke","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib145","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1073\/pnas.94.8.4000","article-title":"Synergy of Taxol and radioimmunotherapy with 90Y-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts","volume":"94","author":"DeNardo","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"S4","key":"10.1016\/j.nucmedbio.2007.04.001_bib146","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/cncr.10303","article-title":"Combined modality radioimmunotherapy: promise and peril","volume":"94","author":"Burke","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib147","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ncpuro0452","article-title":"Technology insight: monoclonal antibody imaging of prostate cancer","volume":"3","author":"Bander","year":"2006","journal-title":"Nat Clin Pract"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib148","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/cncr.10337","article-title":"Clinical utility of 111In-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy","volume":"94","author":"Raj","year":"2002","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib149","first-page":"1017","article-title":"Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49","volume":"35","author":"Meredith","year":"1994","journal-title":"J Nucl Med"},{"issue":"19 Pt 2","key":"10.1016\/j.nucmedbio.2007.04.001_bib150","doi-asserted-by":"crossref","first-page":"7195s","DOI":"10.1158\/1078-0432.CCR-1004-0023","article-title":"Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity","volume":"11","author":"Vallabhajosula","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.04.001_bib151","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.10029","article-title":"Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90Y-DOTA-peptide-ChL6","volume":"50","author":"O'Donnell","year":"2002","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.04.001_bib152","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1586\/14737140.5.1.87","article-title":"Monoclonal antibody therapy of ovarian cancer","volume":"5","author":"Nicodemus","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 1","key":"10.1016\/j.nucmedbio.2007.04.001_bib153","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1525-1438.2000.99510.x","article-title":"Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy","volume":"10","author":"Epenetos","year":"2000","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl","key":"10.1016\/j.nucmedbio.2007.04.001_bib154","first-page":"16a","article-title":"A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with 90Y-labeled monoclonal antibody, HMFGI, in ovarian cancer","volume":"23","author":"Seiden","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.nucmedbio.2007.04.001_bib155","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jcp.48.7.631","article-title":"Distribution of Ov-Tl 3 and Mov18 in normal and malignant ovarian tissue","volume":"48","author":"Buist","year":"1995","journal-title":"J Clin Pathol"},{"issue":"11","key":"10.1016\/j.nucmedbio.2007.04.001_bib156","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s002590050335","article-title":"Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration","volume":"25","author":"Buijs","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib157","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00262-005-0693-2","article-title":"90Y labeling of monoclonal antibody MOv18 and pre-clinical validation for radioimmunotherapy of human ovarian carcinomas","volume":"54","author":"Coliva","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.nucmedbio.2007.04.001_bib158","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00003072-199709000-00007","article-title":"Clinical experience with 99mTc-nofetumomab merpentan (Verluma) radioimmunoscintigraphy","volume":"22","author":"Breitz","year":"1997","journal-title":"Clin Nucl Ned"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib159","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/snuc.2002.126053","article-title":"Peptide and antibody imaging in lung cancer","volume":"32","author":"Machac","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.04.001_bib160","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/cbr.2005.20.467","article-title":"Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel administration","volume":"20","author":"Forero","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"issue":"3\u20134","key":"10.1016\/j.nucmedbio.2007.04.001_bib161","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02187762","article-title":"Intralesional administration of 131I-labeled monoclonal antibodies in the treatment of malignant gliomas","volume":"135","author":"Arista","year":"1995","journal-title":"Acta Neurochir"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.04.001_bib162","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/14712598.6.5.539","article-title":"131I-chTNT-1\/B mAb: tumor necrosis therapy for malignant astrocytic glioma","volume":"6","author":"Shapiro","year":"2006","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.04.001_bib163","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ijc.2910610414","article-title":"Bispecific monoclonal antibody anti-Cd3 X anti-tenascin \u2014 an immunotherapeutic agent for human glioma","volume":"61","author":"Bonino","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib164","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01052668","article-title":"Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan Mel-14 F(ab\u2032)2 preliminary report","volume":"24","author":"Bigner","year":"1995","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.04.001_bib165","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.20.5.1389","article-title":"Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas","volume":"20","author":"Reardon","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.04.001_bib166","first-page":"1042","article-title":"Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study","volume":"46","author":"Akabani","year":"2005","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.04.001_bib167","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/10849780152389410","article-title":"Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results","volume":"16","author":"Paganelli","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib168","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bjc.6600047","article-title":"Pre-targeted adjuvant radioimmunotherapy with 90Y-biotin in malignant glioma patients: a pilot study","volume":"86","author":"Grana","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib169","first-page":"2729","article-title":"Phase I\/II radioimmunotherapy trial with 131I-labeled monoclonal antibody G250 in metastatic renal cell carcinoma","volume":"4","author":"Divgi","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.04.001_bib170","first-page":"1412","article-title":"Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer","volume":"45","author":"Divgi","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib171","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00262-002-0348-5","article-title":"Advancing role of radiolabeled antibodies in the therapy of cancer","volume":"52","author":"Goldenberg","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib172","unstructured":"Projection based on Sg2 Imaging Forcast, U.M.-S., Skokie, IL (www.sg2.com)."},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib173","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1097\/01.ju.0000120241.50061.e4","article-title":"Clinical use of fluorodeoxyglucose 18F positron emission tomography for detection of renal cell carcinoma","volume":"171","author":"Kang","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib174","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10434-001-0779-9","volume":"8","author":"Libutti","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib175","unstructured":"Wittes RE. Cancer weapons, out of reach. The Washington Post June 28, 2004."},{"key":"10.1016\/j.nucmedbio.2007.04.001_bib176","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1148\/radiographics.26.6.0261806","article-title":"Invited commentary","volume":"26","author":"Choyke","year":"2006","journal-title":"Radiographics"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805107000923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805107000923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T20:17:23Z","timestamp":1707941843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805107000923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":176,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0969805107000923"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2007.04.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}